Abstract | OBJECTIVES: BACKGROUND: METHODS: RESULTS: The primary end point occurred in 3.7% of patients treated with atorvastatin reload and in 9.4% in the placebo arm (p = 0.037); this difference was mostly driven by reduction in periprocedural myocardial infarction. There was lower incidence of post-procedural creatine kinase-myocardial band and troponin-I elevation greater than the upper limit of normal in the atorvastatin arm (13% vs. 24%, p = 0.017, and 37% vs. 49%, p = 0.021, respectively). Multivariable analysis identified atorvastatin reload as a predictor of decreased risk of 30-day incidence of major adverse cardiac events (odds ratio: 0.50, 95% confidence interval: 0.20 to 0.80; p = 0.039), mainly in patients with acute coronary syndromes (82% relative risk reduction; p = 0.027). CONCLUSIONS: The ARMYDA-RECAPTURE trial suggests that reloading with high-dose atorvastatin improves the clinical outcome of patients on chronic statin therapy undergoing PCI. These findings may support a strategy of routine reload with high-dose atorvastatin early before intervention even in the background of chronic therapy.
|
Authors | Germano Di Sciascio, Giuseppe Patti, Vincenzo Pasceri, Achille Gaspardone, Giuseppe Colonna, Antonio Montinaro |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 54
Issue 6
Pg. 558-65
(Aug 04 2009)
ISSN: 1558-3597 [Electronic] United States |
PMID | 19643320
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Atorvastatin
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
- Atorvastatin
- Combined Modality Therapy
- Coronary Artery Disease
(therapy)
- Double-Blind Method
- Female
- Heptanoic Acids
(pharmacology, therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Pyrroles
(pharmacology, therapeutic use)
- Treatment Outcome
|